GlassScriptPhysician profile
Xuyen Ha
NPI 1780144675
$2,943.72
in general payments reported to CMS, 2019-2025
27 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.10 · 2020: $18.71 · 2021: $136 · 2022: $227 · 2023: $750 · 2024: $1,062 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $666.07 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $344.84 | 2023-2025 | Ozempic, Wegovy |
| Pfizer INC. | $332.11 | 2022-2025 | |
| Abbvie INC. | $328.74 | 2022-2025 | |
| Glaxosmithkline, LLC. | $195.30 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $183.11 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $131.55 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Hydrocision, INC. | $127.11 | 2024 | Tenjet |
| Hologic Sales and Service, LLC | $103.81 | 2025 | Acessa Provu System |
| Biohaven Pharmaceuticals, INC. | $103.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $48.65 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $37.23 | 2023 | Qelbree |
| Amgen INC. | $33.64 | 2021-2022 | |
| Gilead Sciences, INC. | $33.30 | 2020-2021 | |
| Mylan Specialty L.P. | $27.38 | 2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.65 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $26.21 | 2022 | |
| Dexcom, INC. | $24.24 | 2024 | Dexcom G6 Transmitter |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.44 | 2025 | |
| Collegium Pharmaceutical, INC. | $23.37 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $22.63 | 2024 | Spravato |
| Sumitomo Pharma America, INC. | $22.11 | 2025 | Gemtesa |
| Ironshore Pharmaceuticals INC. | $21.07 | 2022 | |
| Currax Pharmaceuticals LLC | $15.58 | 2025 | Contrave |
| Genentech USA, INC. | $15.10 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.88 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xuyen Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.